A polemic in response to Goudemand et al. (Blood 2006). The main question on Goudemand et al.'s study deals with the validity of comparing inhibitor incidence in very different cohort. Another questionable point is that in 10 patients of the plasma-derived FVIII cohort treated before 1991, the quant. Bethesda inhibitor assay was used only to confirm inhibitors suspected on the basis of a semiquant. test based upon the partial thromboplastin time, while all the recombinant FVIII-treated patients were evaluated from the onset of the Bethesda assay. [on SciFinder (R)]
Assessing the risk of inhibitor formation with different factor VIII products / Pier Mannuccio Mannucci. - In: BLOOD. - ISSN 0006-4971. - 107:9(2006), pp. 3809-3810.
Assessing the risk of inhibitor formation with different factor VIII products
Pier Mannuccio Mannucci
2006
Abstract
A polemic in response to Goudemand et al. (Blood 2006). The main question on Goudemand et al.'s study deals with the validity of comparing inhibitor incidence in very different cohort. Another questionable point is that in 10 patients of the plasma-derived FVIII cohort treated before 1991, the quant. Bethesda inhibitor assay was used only to confirm inhibitors suspected on the basis of a semiquant. test based upon the partial thromboplastin time, while all the recombinant FVIII-treated patients were evaluated from the onset of the Bethesda assay. [on SciFinder (R)]
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
